These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26092065)

  • 21. Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance.
    Foster SA; Foley KA; Meadows ES; Johnston JA; Wang SS; Pohl GM; Long SR
    Osteoporos Int; 2011 Feb; 22(2):551-7. PubMed ID: 20798929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Time of Administration of Teriparatide on Bone Mineral Density in Glucocorticoid-Induced Osteoporosis.
    Mastaglia SR
    J Clin Densitom; 2017; 20(4):513-515. PubMed ID: 28579148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacologic treatment of osteoporosis--2011].
    Lakatos P
    Orv Hetil; 2011 Aug; 152(33):1320-6. PubMed ID: 21824859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Osteoporosis].
    Uelbelhart B; Rizzoli R
    Rev Med Suisse; 2012 Jan; 8(324):109-10, 112-5. PubMed ID: 23185820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study description and baseline characteristics of the population enrolled in a multinational observational study of extended teriparatide use (ExFOS).
    Ljunggren O; Benhamou CL; Dekker J; Kapetanos G; Kocjan T; Langdahl BL; Napoli N; Petto H; Nikolić T; Lindh E
    Curr Med Res Opin; 2014 Aug; 30(8):1607-16. PubMed ID: 24720366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Teriparatide: new indication. During corticosteroid therapy: no fewer clinical fractures. Unnecessarily inconvenient.
    Prescrire Int; 2009 Aug; 18(102):159. PubMed ID: 19743573
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report.
    Nishikawa A; Ishida T; Taketsuna M; Yoshiki F; Enomoto H
    Clin Interv Aging; 2016; 11():913-25. PubMed ID: 27462147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of teriparatide in osteoporotic fracture patients.
    Collinge C; Favela J
    Injury; 2016 Jan; 47 Suppl 1():S36-8. PubMed ID: 26768289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effect of Teriparatide on Fracture Healing of Osteoporotic Patients: A Meta-Analysis of Randomized Controlled Trials.
    Lou S; Lv H; Wang G; Zhang L; Li M; Li Z; Zhang L; Tang P
    Biomed Res Int; 2016; 2016():6040379. PubMed ID: 27429980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteoporosis Management Following Teriparatide Therapy For Vertebral Fractures: Are Patients On Correct Maintenance Therapy?
    O'Connor MB; Bond U; Yousif T
    Ir Med J; 2018 Mar; 111(3):724. PubMed ID: 30376242
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effects of parathyroid hormone (teriparatide) on bone quality in osteoporosis].
    Saito M; Marumo K
    Clin Calcium; 2012 Mar; 22(3):343-55. PubMed ID: 22370301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Process in development of PTH, an awaited bone-density conservation agent].
    Sugimoto T
    Clin Calcium; 2012 Mar; 22(3):307. PubMed ID: 22893932
    [No Abstract]   [Full Text] [Related]  

  • 33. Teriparatide may accelerate healing in delayed unions of type III odontoid fractures: a report of 3 cases.
    Rubery PT; Bukata SV
    J Spinal Disord Tech; 2010 Apr; 23(2):151-5. PubMed ID: 20051918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide.
    Tanaka S; Kuroda T; Sugimoto T; Nakamura T; Shiraki M
    Curr Med Res Opin; 2014 May; 30(5):931-6. PubMed ID: 24392946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
    Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
    Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combination or sequential treatment using PTH and anti-resorption therapies].
    Suzuki H; Takeuchi Y
    Clin Calcium; 2012 Mar; 22(3):415-20. PubMed ID: 22370309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Author's response to letter to the editor.
    Tanaka S; Kuroda T; Sugimoto T; Nakamura T; Shiraki M
    Curr Med Res Opin; 2014 Aug; 30(8):1627-8. PubMed ID: 24730639
    [No Abstract]   [Full Text] [Related]  

  • 38. Short-term treatment experience with teriparatide in pregnancy- and lactation-associated osteoporosis.
    Coskun Benlidayi I; Sarpel T; Guzel R
    J Obstet Gynaecol; 2014 Nov; 34(8):736. PubMed ID: 24911426
    [No Abstract]   [Full Text] [Related]  

  • 39. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
    Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
    Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of osteoporosis with PTH].
    Takeuchi Y
    Clin Calcium; 2014 Jun; 24(6):893-902. PubMed ID: 24870841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.